An interactive research-focused summary of tirzepatide, a dual GIP and GLP-1 receptor agonist, with visualized outcomes across weight management, glycemic control, sleep apnea, liver disease, and cardiometabolic endpoints.
Efficacy snapshot
Tirzepatide has been evaluated across large Phase 3 programs in obesity and type 2 diabetes, with additional research in obstructive sleep apnea, MASH, and heart failure with preserved ejection fraction in adults with obesity.
The molecule combines GLP-1 receptor activity, associated with satiety and glucose-dependent insulin secretion, with GIP receptor activity, which is studied for effects on insulin sensitivity, metabolic regulation, and adipose-tissue biology.
SURMOUNT-4 illustrates the chronic-care nature of obesity management: continued treatment maintained and extended weight reduction, while withdrawal was associated with regain.
SURMOUNT-5 compared tirzepatide with semaglutide in adults with obesity or overweight without diabetes, adding direct comparative context to the evidence base.
Evidence now includes clinically relevant endpoints in sleep apnea, liver disease, and obesity-related HFpEF, making tirzepatide one of the most extensively studied incretin therapies.
Pharmacology
Tirzepatide is an imbalanced dual agonist, engineered to favor GIP receptor binding over GLP-1 receptor binding, mimicking the natural metabolic synergy of endogenous incretin hormones.
Glucagon-like peptide-1 (GLP-1) agonism predominantly regulates glucose metabolism by enhancing glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion. It slows gastric emptying and operates centrally in the brain to signal satiety and reduce caloric intake.
Glucose-dependent insulinotropic polypeptide (GIP) agonism acts synergistically with GLP-1. Modulating the GIP receptor has been shown in pre-clinical and clinical models to enhance insulin sensitivity, improve lipid metabolism, and regulate white adipose tissue function, limiting ectopic fat deposition.
Interactive infographics
Hover over the charts to review primary efficacy endpoints drawn from the SURMOUNT and SURPASS clinical programs. Charts will animate as you scroll them into view.
Endpoint summary
A concise overview of the main clinical themes represented in tirzepatide's published and regulatory evidence base.
| Research area | Study / setting | Reported signal | Why it matters |
|---|---|---|---|
| Chronic weight management | SURMOUNT-1; 72 weeks | Up to 20.9% mean body-weight reduction at 15 mg | Established dual-incretin therapy as a major pharmacologic approach for obesity research. |
| Obesity with Type 2 Diabetes | SURMOUNT-2; 72 weeks | Up to 15.7% mean body-weight reduction at 15 mg | Demonstrated significant weight reduction in a clinical population typically resistant to weight loss. |
| Active comparator obesity | SURMOUNT-5; 72 weeks | 20.2% mean reduction with tirzepatide vs 13.7% with semaglutide | Provides direct head-to-head context against a single GLP-1 receptor agonist. |
| Type 2 diabetes | SURPASS-2; 40 weeks | Up to 2.30% mean HbA1c reduction at 15 mg | Demonstrated strong glycemic control against semaglutide 1 mg. |
| Obstructive sleep apnea | SURMOUNT-OSA; 52 weeks | Clinically meaningful reductions in apnea-hypopnea events | Supported the first FDA approval of a medication for moderate-to-severe OSA in adults with obesity. |
| MASH / liver fibrosis | SYNERGY-NASH; 52 weeks | High-dose group reported 74% MASH resolution without worsening fibrosis | Positions liver disease as a key cardiometabolic research extension. |
| HFpEF with obesity | SUMMIT; median follow-up about two years | Lower composite risk of cardiovascular death or worsening heart-failure event vs placebo | Highlights the potential importance of incretin therapy in obesity-related heart failure research. |
Additional resources
Selected newer resources expand the page beyond the original obesity and diabetes dashboard.
Head-to-head comparison of tirzepatide versus semaglutide for obesity treatment without diabetes.
Review summary ↗Obesity-related heart failure with preserved ejection fraction trial evaluating clinical outcomes and health status.
Review summary ↗Regulatory milestone for moderate-to-severe obstructive sleep apnea in adults with obesity.
FDA release ↗Dossier tracks
Select a clinical track below to review study architecture, published endpoints, and mechanistic context.
Design: 72-week trial evaluating 2,539 adults with BMI ≥30, or ≥27 with comorbidities, without diabetes.
Outcomes: The 15 mg dose achieved a 20.9% mean body-weight reduction. A large majority of participants achieved at least 5% weight reduction, establishing a high benchmark for pharmacologic obesity treatment.
Design: Tirzepatide was evaluated after a 12-week intensive lifestyle intervention, where participants had already lost weight through diet and activity changes.
Outcomes: Adding tirzepatide was associated with an additional 21.1% weight reduction, with total mean reduction from study entry reported at 26.6%.
Design: Participants completed a 36-week open-label lead-in, followed by randomized continuation of tirzepatide or switch to placebo.
Outcomes: Continued tirzepatide maintained and extended weight reduction, while withdrawal was associated with substantial weight regain.
Design: 40-week direct comparison of tirzepatide 5, 10, and 15 mg against semaglutide 1 mg in type 2 diabetes.
Outcomes: Tirzepatide 15 mg reduced HbA1c by 2.30% compared with 1.86% for semaglutide and produced greater mean body-weight reduction.
Design: 72-week trial in 938 adults with obesity or overweight and type 2 diabetes.
Outcomes: The 15 mg dose achieved a 15.7% mean body-weight reduction alongside significant improvements in glycemic control, notable for a population historically resistant to pharmacologic weight loss.
Design: Study in participants with type 2 diabetes and increased cardiovascular risk, comparing tirzepatide against titrated insulin glargine.
Outcomes: Tirzepatide produced stronger glycemic control and weight reduction compared with insulin glargine, with cardiovascular safety evaluated in a higher-risk population.
Outcomes: Tirzepatide reduced apnea-hypopnea burden in adults with obesity and moderate-to-severe obstructive sleep apnea, supporting a major new treatment pathway in this population.
Outcomes: The high-dose group reported 74% MASH resolution without worsening fibrosis, with a meaningful proportion also showing fibrosis-stage improvement.
Outcomes: In adults with obesity and heart failure with preserved ejection fraction, tirzepatide lowered the composite risk of cardiovascular death or worsening heart-failure events compared with placebo and improved health-status measures.
Protocol overview
A five-step overview of the dose-escalation structure used to support tolerability in clinical protocols.
Terminology
Metabolic hormones (like GLP-1 and GIP) that are released from the gut into the bloodstream in response to food ingestion, helping to lower blood glucose levels by stimulating insulin release and reducing appetite.
GLP-1 (Glucagon-like peptide-1) primarily regulates appetite and glucose-dependent insulin secretion. GIP (Glucose-dependent insulinotropic polypeptide) acts synergistically to improve insulin sensitivity, regulate lipid metabolism, and may mitigate some GLP-1 related tolerability issues.
Heart Failure with Preserved Ejection Fraction. A condition where the heart pumps normally but is too stiff to fill properly. Incretin therapies are actively being researched for cardiovascular outcome improvements in HFpEF patients with obesity.
Obstructive Sleep Apnea. A sleep-related breathing disorder characterized by repeated episodes of complete or partial airway obstruction.
Researcher FAQ
Dual agonism combines GLP-1 receptor activity with GIP receptor activity, creating a differentiated incretin profile that has been associated with strong body-weight and glycemic outcomes in clinical research. GIP synergy is hypothesized to mitigate some GLP-1 related nausea while promoting improved lipid metabolism and insulin sensitivity.
The most frequent adverse events are gastrointestinal, including nausea, diarrhea, vomiting, constipation, dyspepsia, and abdominal discomfort. These events are typically most prominent during dose escalation and are generally mild to moderate in severity. A step-up titration schedule is utilized to mitigate these effects.
Yes. Tirzepatide, like other incretin-based therapies, carries warnings regarding a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients with a history of severe gastrointestinal disease (e.g., severe gastroparesis) or a history of pancreatitis are typically excluded from trials and advised caution or alternative therapies.
During substantial weight reduction, some lean-mass reduction is expected. Body-composition analyses suggest that most lost mass is fat mass (roughly 75%), with meaningful improvement in overall body composition and cardiometabolic health parameters.
The withdrawal design helps show whether weight reduction is sustained after treatment stops. In SURMOUNT-4, continued treatment maintained and extended weight reduction, while switching to placebo was associated with significant weight regain, demonstrating that obesity generally requires chronic management.
These areas show how tirzepatide research has moved beyond weight and glucose endpoints into obesity-related comorbidities, including sleep-disordered breathing, liver disease, and heart-failure outcomes. This underscores a systemic metabolic improvement rather than just isolated weight loss.